Clinical Trial Update: A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing early versus late onset of epoetin alfa in lower-risk myelodysplastic syndromes. The study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• EPOETIN ALFA (EPOETIN ALFA)

Snippet

Sponsor: Groupe Francophone des Myelodysplasies | Conditions: Myelodysplastic Syndromes | Phase 3 | Status: ACTIVE_NOT_RECRUITING